Benefit-Risk Assessment of the Levonorgestrel Intrauterine System in Contraception

ISSN： 0114-5916

Source： Drug Safety, Vol.27, Iss.15, 2004-01, pp. : 1185-1204

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Levonorgestrel-Releasing Intrauterine System in Heavy Menstrual Bleeding: A Benefit-Risk Review

By Kaunitz Andrew M.

Drugs, Vol. 72, Iss. 2, 2012-01 ,pp. : 193-215

Adis International

Access to resources Recommend Favorite

Levonorgestrel intrauterine system cost effective for contraception

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 468, 2004-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Levonorgestrel intrauterine system cost effective for contraception

Inpharma, Vol. 1, Iss. 1471, 2005-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Development of a miniature, low-dose, frameless intrauterine levonorgestrel-releasing system for contraception and treatment: a review of initial clinical experience

By Wildemeersch Dirk Schacht Etienne Wildemeersch Piet Janssens Dirk Thiery M

Reproductive BioMedicine Online, Vol. 4, Iss. 1, 2002-01 ,pp. : 71-82

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Benefit-Risk Assessment of Irinotecan in Advanced Colorectal Cancer

By Glimelius Bengt

Drug Safety, Vol. 28, Iss. 5, 2005-01 ,pp. : 417-433

Adis International

Access to resources Recommend Favorite